Richard Socarides

5K posts

Richard Socarides banner
Richard Socarides

Richard Socarides

@Socarides

Kozani Capital (early-stage VC). Strategy, communications and Public Affairs.

가입일 Mayıs 2009
789 팔로잉4.1K 팔로워
Richard Socarides 리트윗함
Juan Benet
Juan Benet@juanbenet·
Excited to launch a new podcast dedicated to conversations on the future of neurotech, computing, intelligence, and more. First guest: @maxhodak_ founder & CEO of @ScienceCorp_, which is building PRIMA, a retinal prosthetic that’s restoring meaningful vision for patients with blindness caused by age-related macular degeneration. Science is also developing a biohybrid brain implant that grows living neurons directly onto a silicon chip, then interfaces that system with the cortex. The possibility space here is vast and new. Imagine growing new areas of the brain. Sections 00:00 What counts as neurotech? 01:45 History of brain-computer interfaces and the smartphone dividend 07:25 PRIMA - How Science is restoring vision in blind patients 10:10 Why stimulating bipolar cells works when the optic nerve doesn't 30:30 Are we bottlenecked by biology or engineering? 32:40 Expanding the brain's bandwidth beyond 10 bits per second 37:00 Can we add new areas to the brain? 37:46 Biohybrid BCIs: neurons growing on a chip 39:20 What could neural augmentation look like? 01:13:20 How Science drives Fast R&D 01:44:00 How founders learn and level up This is the kind of discussion I’m excited to explore on this podcast. Enjoy! Full Episode 1 here and in links below.
English
23
72
297
51.5K
Richard Socarides 리트윗함
Science Corporation
Science Corporation@ScienceCorp_·
Science Chief Scientific Officer and Co-Founder @mardinly answers the question “What if we could restore vision, communicate directly with the brain, and even extend human life with living, engineered biology?” Click the link in the comments to watch the full episode.
English
2
4
21
1K
Richard Socarides 리트윗함
NEJM
NEJM@NEJM·
Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in such persons currently exist. NEJM Editorial Fellow Katerina Lin, MD, explains a clinical trial in which the photovoltaic retina implant microarray (PRIMA) system restored central vision and led to a significant improvement in visual acuity. Read the full PRIMAvera trial results: nejm.org/doi/full/10.10… #Ophthalmology
English
0
6
29
13.1K
Richard Socarides 리트윗함
Science Corporation
Science Corporation@ScienceCorp_·
As we accelerate the development of our Biohybrid BCI program, we are thrilled to welcome Dr. Murat Günel as Science's new Medical Director for Brain-Computer Interfaces. Dr. Günel is Chair of Neurosurgery at Yale School of Medicine, Neurosurgeon-in-Chief of Yale New Haven Health System, and a Member of the National Academy of Medicine. Read the blog post in the comments.
English
3
8
51
2.8K
Richard Socarides 리트윗함
Science Corporation
Science Corporation@ScienceCorp_·
"People use [AI] every day, but it is still underestimated the degree to which it is going to change everybody’s lives over the next decade. We’re really now starting to see that. [AI agents] are no longer just a curiosity. They’re now having economic impacts that are going to accelerate." Science CEO, Max Hodak, joined @POLITICO for 5 Questions: politico.com/newsletters/di…
English
1
8
31
1.6K
Richard Socarides 리트윗함
Science Corporation
Science Corporation@ScienceCorp_·
“It’s the first time that any attempt at vision restoration has achieved such results in a large number of patients… This is really something we couldn’t have dreamt of when we started on this journey more than two decades ago.” In a new interview, José-Alain Sahel, MD, a senior author of the PRIMA clinical trial now published in @NEJM, shares his opinion on the resilience required to turn a decades-old concept into clinical reality.
Science Corporation tweet media
English
1
9
36
2.1K
Richard Socarides 리트윗함
Science Corporation
Science Corporation@ScienceCorp_·
We’ve closed a $230 million Series C financing. The deal was oversubscribed with demand in excess of our capital needs, and brings the total capital invested into the company to approximately $490 million since our founding in 2021.
Science Corporation tweet media
English
5
9
105
10.4K
Richard Socarides 리트윗함
Science Corporation
Science Corporation@ScienceCorp_·
We have partnered with @NeurosoftBio, a neural data company developing ultra-soft, flexible neural probes to achieve full cortical coverage powering foundation AI models of the brain, to grant Neurosoft access to Science’s world-class clinical-grade neural engineering capabilities known as the Science Ecosystem.
Science Corporation tweet media
English
4
11
85
6.5K
Richard Socarides 리트윗함
Science Corporation
Science Corporation@ScienceCorp_·
“We found that patients [in clinical trials] were able to regain the ability to read – not fast, not quickly, but they really could start to read again using a retinal prosthesis.” Frank Brodie, MD, Science’s Medical Director for Vision and PRIMA, joined @_BrightFocus to discuss the PRIMA brain-computer interface (BCI) retinal implant, the first treatment shown in clinical trials to restore functional vision for geographic atrophy due to AMD. Listen to the entire discussion here: brightfocus.org/resource/can-r…
English
0
4
15
669
Richard Socarides 리트윗함
Science Corporation
Science Corporation@ScienceCorp_·
An editorial published today in @NEJM writes that our PRIMA implant is the first treatment in clinical trials to successfully restore functional vision to certain patients suffering from geographic atrophy due to age-related macular degeneration, a leading cause of blindness affecting more than 5 million people worldwide.
English
1
8
30
2.9K
Richard Socarides 리트윗함
Max Hodak
Max Hodak@maxhodak_·
from the start there’s always been a 3rd program in our pipeline, though it’s taken a backseat to the BCIs; an idea that’s highly complementary though distinct still have a long road ahead, but we‘re ready to go a bit faster now and are staffing up our Vessel program:
Science Corporation@ScienceCorp_

Today we announced Vessel, a project focused on rethinking perfusion from the ground up, extending how long life can be sustained, and expanding what’s possible in transplantation and critical care. Life-support technologies like ECMO can keep patients alive when the heart or lungs fail, but they aren’t designed for long-term use. Vessel exists to close the gap between what perfusion technology is fundamentally capable of and how it is deployed in daily practice. Our founder and CEO Max Hodak spoke with @WIRED's @emilylmullin about how neural interfaces and Vessel are both longevity technologies, and that is the goal of Science. wired.com/story/a-brain-…

English
9
9
119
20.5K
Richard Socarides 리트윗함
Icons
Icons@sv_icons·
We've hosted the KING of BCI 🧠✨
Georgi Koreli@gegelz

Last week, we had a chance to host @maxhodak_ , founder of @ScienceCorp_ and Co-Founder of Neuralink, for @sv_icons dinner. It was one of the most fascinating conversations we’ve had at Icons, covering topics ranging from the future of brain-computer interfaces to learnings that Max had after co-founding company with Elon Musk. Here are a few insights from the conversation: - Max starts from a blunt premise: the current human condition is mediocre, and the whole point of brain–computer interfaces are not only to treat pathology, but to reengineer the human experience. - He sees the next 10 years as a phase transition: with AI and BCIs compounding at today’s pace, our world will end up either absolutely beautiful or absolutely crazy, but definitely not a slightly different version of 2025. - Max frames AI and BCIs as two distinct technological quests. If the end goal of artificial intelligence is superintelligence, the end goal of the BCI quest is a conscious machine. Classical BCIs are about reading and writing information to and from the brain—extracting motor representations to control a cursor or keyboard, or writing sensory information to restore vision, hearing, or proprioception. But he believes a non-classical form of BCI is on the horizon. Instead of reading or writing information, these systems would enable phenomenal binding over a network. That would be a fundamentally different kind of technology, and if it works, it wouldn’t just improve human capabilities – it would qualitatively transform the human condition. - Reasoning is, in his view, the most important capability humans brains have — and widespread LLM use quietly erodes it, which is why he actively restricts LLMs at work and pushes people to keep doing hard, first-principles thinking themselves. - Max co-founded Neuralink with Elon and speaks very highly of his management skills: when you put extreme urgency at the center of decision making among people with the highest level of critical thinking - impossible things become possible. - One of the big observations that Max had is that the statement of risk is overrated. People can take way higher risks but they don’t have enough agency to think clearly about such risks. He shares the example of Silicon Valley founders - almost everyone can raise money and then if things don’t work - join a big tech firm. No risk is involved. - Max describes a biohybrid approach to BCIs built from stem-cell–derived biological neurons. Instead of placing mechanical or electrical devices into the brain, the idea is to embed engineered neurons into a device and engraft it onto the brain’s surface. The question is whether those cells would grow in and form functional connections – and the answer is yes. Even a tiny graft, on the order of four millimeters by four millimeters, can integrate extensively. Because cells are small, such a device can contain on the order of a million neurons, forming billions of synapses. Max sees this as a genuinely new kind of system, and possibly the first plausible path to a whole-brain – or interhemispheric-bandwidth – neural interface. - Consciousness is independent from intelligence. LLMs have intelligence but don’t have consciousness. Conversely, non-intelligent objects might have consciousness. One of the problems with consciousness is defining it, we all know it exists, but it always has a broad definition. - Causing visual hallucinations via video is possible but the implications are very limited. - During interviews, the most important quality that Max checks is agency. Agency in making all the decisions people made to get where they are or they just followed the flow? - Max’s definition of success for someone is this: does this person have the life they wanted to have? And it doesn’t necessarily have to be rich or luxury life. Someone wants to have good work-life balance and hang out with friends - does this person have this? - His long-term economic thesis is that powerful tech will drive us into a state of abundance, and once that happens, capital and opportunity can be distributed far more equally, making today’s rich-vs-poor discourse feel oddly outdated. - Max thinks about neural engineering from the bottom up: his work is largely in low-level cognition and neural mechanics, even when he talks in terms of high-level concepts like consciousness and identity. - One of the biggest problems to scale BCI is 10 bits-per-second bottleneck of human output. You can increase input, but how can you scale output? It might be possible biohybrid approaches using stem-cell-derived neurons that integrate into the brain, and breaking by directly serializing thought. - He’s deeply interested in the “binding problem” of consciousness — how billions of neurons over space and time become a single unified “moment,” and why you only ever experience your bundle of sensory modes together rather than, say, your vision and someone else’s hearing. - His working hypothesis is that consciousness is tied to physically realized information and thermodynamics: whenever a system burns energy to stabilize a representation against entropy, you get qualia — an idea he’s honest about holding with medium-low epistemic confidence but sees as concrete enough for a real research program. - On ethics and regulation, he argues that concerns around “neural privacy” are often overstated, and that overly restrictive rules around pooling brain data are slowing down progress on exactly the science that could make BCIs safe, useful, and eventually life-changing.

English
0
1
8
380
Richard Socarides 리트윗함
Science Corporation
Science Corporation@ScienceCorp_·
Today we announced Vessel, a project focused on rethinking perfusion from the ground up, extending how long life can be sustained, and expanding what’s possible in transplantation and critical care. Life-support technologies like ECMO can keep patients alive when the heart or lungs fail, but they aren’t designed for long-term use. Vessel exists to close the gap between what perfusion technology is fundamentally capable of and how it is deployed in daily practice. Our founder and CEO Max Hodak spoke with @WIRED's @emilylmullin about how neural interfaces and Vessel are both longevity technologies, and that is the goal of Science. wired.com/story/a-brain-…
English
14
43
363
120.9K
Richard Socarides 리트윗함
Max Hodak
Max Hodak@maxhodak_·
Some team updates at Science! My cofounder @mardinly has become Chief Scientific Officer Darius Shahida, an investor since the B, is joining full time to help turn our amazing technologies into an amazing business science.xyz/news/leadershi…
English
4
10
143
9.6K
Richard Socarides 리트윗함
Science Corporation
Science Corporation@ScienceCorp_·
Welcome Darius Shahida, our new Chief Strategy Officer. As we continue to accelerate into our mission to transcend the limits of biology, Darius brings deep experience in strategic growth, capital markets, and scaling category-defining technology companies. Read the press release in the comments. businesswire.com/news/home/2025…
English
1
3
17
2.2K